{"classes":[{"categories":[{"measurements":[{"comment":"Not estimable.","groupId":"OG000","lowerLimit":"7.1","upperLimit":"NA","value":"14.7"},{"groupId":"OG001","lowerLimit":"7.2","upperLimit":"19.9","value":"10.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"39"}],"units":"Participants"}],"description":"Median time to death was analyzed by the Kaplan-Meier approach for each tumor type.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with NSCLC received PF-06801591 300 mg SC every 4 weeks for 28-day cycles. (maximum of 851 days)","id":"OG000","title":"Part 2: PF-06801591 300 mg (SC) for NSCLC"},{"description":"Participants with UC received PF- 06801591 300 mg SC every 4 weeks for 28-day cycles. (maximum of 841 days)","id":"OG001","title":"Part 2: PF-06801591 300 mg (SC) for UC"}],"paramType":"MEDIAN","populationDescription":"Analysis population included all the randomized participants who received at least 1 dose of study medication, had measurable disease baseline assessment (within 28 days prior to study entry) and at least 1 post baseline assessment or disease progression, global deterioration of health status, or death.","reportingStatus":"POSTED","timeFrame":"Baseline up to end of treatment in Part 2 (maximum of 851 days)","title":"Median Time to Death - Part 2","type":"SECONDARY","unitOfMeasure":"Months"}